EVO vs BCRX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
EVO · Evotec$1.32 ▼ 8.97%
BCRX · BioCryst Pharmaceuticals$7.22 ▼ 1.37%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- EVO -56.4%
- BCRX +5.7%
Head to head
| Metric | EVO | BCRX |
|---|---|---|
| Price | $1.32 | $7.22 |
| Change today | ▼ 8.97% | ▼ 1.37% |
| Market cap | $469.11M | $1.86B |
| Return, 3 months | -30.2% | -25.4% |
| Return, year to date | -57.1% | -7.4% |
| Return, 1 year | -55.6% | +3.6% |
| P/E (TTM) | – | – |
| P/B | 0.7 | -4.7 |
| P/E percentile vs own 5y | 77th | 70th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +0.6% | +13.1% |
| Net profit growth (YoY) | +37.9% | +193.9% |
| Gross margin | 10.3% | 97.9% |
| Operating margin | -17.5% | 42.5% |
| Net margin | -25.2% | -37.4% |
| Return on equity | -25.1% | – |
| Analyst target vs. price | +278.8% | +135.5% |
| Analyst buy share | 100% | 67% |
| RSI (14) | 32 | 35 |
| 30-day volatility | 72.7% | 40.4% |
| Max drawdown, 1 year | -65.9% | -35.0% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BCRX is the largest of the group by market value.
- BCRX has returned the most over the past year.
- BCRX is growing revenue fastest.
- EVO keeps the most profit per dollar of sales.
- BCRX has been the calmest stock over the last 30 days.